SCPH (scPharmaceuticals) Research & Development : $14.00 Mil (TTM As of Mar. 2025)

View and export this data going back to 2017. Start your Free Trial

What is scPharmaceuticals Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. scPharmaceuticals's Research & Development for the three months ended in Mar. 2025 was $4.63 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 was $14.00 Mil.

scPharmaceuticals Research & Development Historical Data

The historical data trend for scPharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

scPharmaceuticals Research & Development Chart

scPharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Research & Development

Get a 7-Day Free Trial

18.15

16.04

15.53

11.81

12.10

scPharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Research & Development	Get a 7-Day Free Trial															2.73	2.68	3.54	3.15	4.63

scPharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $14.00 Mil.

scPharmaceuticals (NAS:SCPH) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

scPharmaceuticals Research & Development Related Terms

Thank you for viewing the detailed overview of scPharmaceuticals's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

scPharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » scPharmaceuticals Inc (NAS:SCPH) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

2SX:Germany

Address

25 Mall Road, Suite 203, Burlington, MA, USA, 01803

Website

https://www.scpharmaceuticals.com

scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.

Executives

Orbimed Advisors Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
5am Partners Iv, Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Jack A. Khattar	director	C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
John H Tucker	director, officer: President and CEO	INDEVUS PHARMACEUTICALS, INC., 99 HAYDEN AVENUE, LEXINGTON MA 02421
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
William Tober Abraham	director	C/O SCPHARMACEUTICALS INC., 2400 DISTRICT AVENUE, SUITE 310, BURLINGTON MA 01803
Sara Bonstein	director	305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Andrew J. Schwab	10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I (gp), Llc	other: See Remarks	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I, L.p.	other: See Remarks	501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107
Orbimed Genesis Gp Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Peter Kolchinsky	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p.	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rachael Nokes	officer: See Remarks	C/O SCPHARMACEUITCALS, INC., 2400 DISTRICT AVENUE, BURLINGTON MA 01803